Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar Therapeutics, specializes in creating novel therapies aimed at selectively modulating pathways within the immune system that play critical roles in a wide range of serious diseases. Specifically in autoimmune disorders, Nektar's focus is on addressing imbalances in the immune system to restore the body’s self-tolerance mechanisms and achieve immune homeostasis. Nektar is headquartered in San Francisco, California, with additional manufacturing operations in Huntsville, Alabama.